BR0107930A - Métodos de identificação de elementos reguladores transcricionais e translacionais sintéticos, e composições relativas aos mesmos - Google Patents

Métodos de identificação de elementos reguladores transcricionais e translacionais sintéticos, e composições relativas aos mesmos

Info

Publication number
BR0107930A
BR0107930A BR0107930-1A BR0107930A BR0107930A BR 0107930 A BR0107930 A BR 0107930A BR 0107930 A BR0107930 A BR 0107930A BR 0107930 A BR0107930 A BR 0107930A
Authority
BR
Brazil
Prior art keywords
transcriptional
identifying
translational
methods
regulatory elements
Prior art date
Application number
BR0107930-1A
Other languages
English (en)
Inventor
Vincent P Mauro
Gerald M Edelman
Stephen A Chappell
Frederick S Jones
Geoffrey Owens
Robyn Meech
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BR0107930A publication Critical patent/BR0107930A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"MéTODOS DE IDENTIFICAçãO DE ELEMENTOS REGULADORES TRANSCRICIONAIS E TRANSLACIONAIS SINTéTICOS, E COMPOSIçõES RELATIVAS AOS MESMOS". São fornecidos métodos de identificação de oligonucleotídeos tendo atividade transcricional ou translacional integrando o oligonucleotídeo em um genona de célula eucariótica tal que o oligonucleotídeo seja operativamente ligado a um polinucleotídeo expressível, e detectar uma alteração em expressão do polinucleotídeo expressível devido ao oligonucleotídeo operativamente ligado. São também fornecidos vetores úteis para a identificação de um oligonucleotídeo tendo atividade reguladora translacional ou transcricional de acordo com um método da invenção. Além disso, elementos reguladores transcricionais ou translacionais sintéticos isolados identificados de acordo com um método da invenção são fornecidos, assim como são os kits, que contêm um vetor útil para a identificação de um elemento regulador transcricional ou translacional, ou um elemento regulador transcricional ou translacional sintético isolado ou pluralidade de tais elementos. São também fornecidos elementos reguladores transcricionais isolados.
BR0107930-1A 2000-01-28 2001-01-26 Métodos de identificação de elementos reguladores transcricionais e translacionais sintéticos, e composições relativas aos mesmos BR0107930A (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17881600P 2000-01-28 2000-01-28
US18649600P 2000-03-02 2000-03-02
US20780400P 2000-05-30 2000-05-30
US23085200P 2000-09-07 2000-09-07
US23095600P 2000-09-07 2000-09-07
US26131201P 2001-01-12 2001-01-12
PCT/US2001/002733 WO2001055371A1 (en) 2000-01-28 2001-01-26 Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same

Publications (1)

Publication Number Publication Date
BR0107930A true BR0107930A (pt) 2004-06-15

Family

ID=27558689

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0107943-3A BR0107943A (pt) 2000-01-28 2001-01-26 Sìtios de entrada de ribossoma internos sintéticos e métodos de identificar os mesmos
BR0107930-1A BR0107930A (pt) 2000-01-28 2001-01-26 Métodos de identificação de elementos reguladores transcricionais e translacionais sintéticos, e composições relativas aos mesmos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0107943-3A BR0107943A (pt) 2000-01-28 2001-01-26 Sìtios de entrada de ribossoma internos sintéticos e métodos de identificar os mesmos

Country Status (6)

Country Link
US (3) US7183395B2 (pt)
EP (2) EP1274838A1 (pt)
AU (4) AU2001231171B2 (pt)
BR (2) BR0107943A (pt)
CA (2) CA2398790A1 (pt)
WO (2) WO2001055369A1 (pt)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001231171B2 (en) * 2000-01-28 2007-01-04 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying same
DE10049587A1 (de) 2000-10-06 2002-05-02 Icon Genetics Ag Vektorsystem für Pflanzen
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
WO2002070746A2 (en) * 2001-03-01 2002-09-12 Cistem Molecular Corporation Methods for global profiling gene regulatory element activity
EP1373481A4 (en) * 2001-03-07 2005-04-13 Xenogen Corp PROCESS FOR SCREENING ON THE INTRODUCTION OF DNA TO A TARGET CELL
EP1373885A4 (en) * 2001-03-29 2004-06-23 Evogene Ltd METHODS, PLATFORMS AND KITS SUITABLE FOR IDENTIFYING, ISOLATING AND USING GENE EXPRESSION IN AN ORGANISM REGULATING NUCLEOTIDE SEQUENCES
DE10121283B4 (de) 2001-04-30 2011-08-11 Icon Genetics GmbH, 80333 Verfahren und Vektoren zur Amplifikation oder Expression von gewünschten Nucleinsäuresequenzen in Pflanzen
EP1412493B1 (en) 2001-08-02 2011-10-05 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
DE10143238A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Identifizierung eukaryotischer interner Ribosomen-Eingangsstellen (IRES)-Elemente
DE10143237A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
IL161229A0 (en) * 2001-10-02 2004-09-27 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications.
US20080076678A1 (en) 2005-06-15 2008-03-27 Philippe Soucaille Method of creating a library of bacterial clones with varying levels of gene expression
ATE509946T1 (de) * 2002-11-12 2011-06-15 Zakrytoe Aktsionernoe Obschestvo S Evrogens Fluoreszenzproteine und chromoproteine aus nicht- aequorea-hydrozoa-spezies sowie verfahren zur verwendung davon
EP1606304A4 (en) 2003-03-12 2006-09-27 Evogene Ltd Gene expression regulating regulatory nucleotide sequences and constructs and methods thereof
US20050037409A1 (en) * 2003-07-29 2005-02-17 Kauvar Lawrence M. Translocation tagging
US8293503B2 (en) 2003-10-03 2012-10-23 Promega Corporation Vectors for directional cloning
CA2541177A1 (en) * 2003-10-03 2005-09-22 Promega Corporation Vectors for directional cloning
EP1743028A2 (en) * 2004-04-28 2007-01-17 The Trustees Of The University Of Pennsylvania Polyvalent viral vectors and a system for production thereof
US7709625B2 (en) * 2004-06-10 2010-05-04 The Board Of Regents Of The University Of Texas Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy
WO2007025008A2 (en) 2005-08-24 2007-03-01 The Scripps Research Institute Translation enhancer-element dependent vector systems
WO2007025190A2 (en) * 2005-08-25 2007-03-01 Whitehead Institute For Biomedical Research Novel methods for genome-wide location analysis
WO2007038757A2 (en) * 2005-09-28 2007-04-05 Attagene Inc. Methods and compositions for non-invasive assessment of gene expression
JPWO2007097443A1 (ja) * 2006-02-20 2009-07-16 国立大学法人 北海道大学 Ｄｎａ塩基配列を決定する方法
EP2405272B1 (en) * 2006-06-30 2015-01-14 DiscoveRx Corporation Detectable nucleic acid tag
CA2735575A1 (en) * 2007-08-10 2009-02-19 Wayne State University Compositions and methods for detecting and modulating cell death by a translation regulated gene expression system
DK3156414T3 (da) * 2007-09-26 2020-03-09 Intrexon Corp Syntetisk 5'utrs ekspressionsvektorer og fremgangsmåder til øgning af transgen ekspression
CA2904904A1 (en) * 2007-12-11 2009-06-18 The Scripps Research Institute Compositions and methods related to mrna translational enhancer elements
GB2480413B (en) 2009-02-18 2014-12-24 Univ Wayne State Method for identifying a subpopulation of mammalian cells with distinctive ribosome translation profiles
WO2010124157A1 (en) 2009-04-24 2010-10-28 Ambit Biosciences Corporation Cellular assay employing detectable protein
WO2012009644A2 (en) * 2010-07-16 2012-01-19 Arizona Board Of Regents Methods to identify synthetic and natural rna elements that enhance protein translation
KR101890446B1 (ko) * 2010-11-08 2018-08-21 제이씨알 파마 가부시키가이샤 신규 발현 벡터
EP2705152B1 (en) * 2011-05-04 2017-10-25 The Broad Institute, Inc. Multiplexed genetic reporter assays and compositions
CN102517282B (zh) * 2011-12-30 2013-10-30 中国人民解放军军事医学科学院放射与辐射医学研究所 一种富集分离内源转录因子及其复合物的方法及其专用转录因子串联结合序列
US20140107589A1 (en) * 2012-10-17 2014-04-17 Farid Amirouche Electromagnetically actuated valve and related methods of use
EP4074834A1 (en) 2012-11-26 2022-10-19 ModernaTX, Inc. Terminally modified rna
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
EP2946014A2 (en) 2013-01-17 2015-11-25 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
EP2801622A1 (en) * 2013-05-08 2014-11-12 DeltaCell B.V. Multi-tag reporter system
WO2014186334A1 (en) * 2013-05-15 2014-11-20 Robert Kruse Intracellular translation of circular rna
EA035313B1 (ru) * 2013-11-12 2020-05-27 Врейе Университейт Брюссель Транскрипционный днк-вектор и его применения
GB201406006D0 (en) * 2014-04-03 2014-05-21 Norwegian Univ Sci & Tech Ntnu Synthetic mRNA leaders
EP3461904A1 (en) 2014-11-10 2019-04-03 ModernaTX, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
PL3350333T3 (pl) 2015-09-17 2022-03-07 Modernatx, Inc. Polinukleotydy zawierające region stabilizujący ogon
PT3350157T (pt) 2015-09-17 2022-03-18 Modernatx Inc Compostos e composições para administração intracelular de agentes terapêuticos
US10849920B2 (en) 2015-10-05 2020-12-01 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
WO2017066781A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
EP3362460A1 (en) 2015-10-16 2018-08-22 Modernatx, Inc. Mrna cap analogs and methods of mrna capping
AU2016377681B2 (en) 2015-12-22 2021-05-13 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US10689689B2 (en) * 2015-12-28 2020-06-23 Roche Molecular Systems, Inc. Generic method for the stabilization of specific RNA
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2017180917A2 (en) 2016-04-13 2017-10-19 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
MA45052A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
RU2769316C2 (ru) 2016-05-18 2022-03-30 МОДЕРНАТиЭкс, ИНК. Полинуклеотиды, кодирующие интерлейкин-12 (il12), и их применения
WO2017218704A1 (en) 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
DE102017103383A1 (de) * 2017-02-20 2018-08-23 aReNA-Bio GbR (vertretungsberechtigter Gesellschafter: Dr. Heribert Bohlen, 50733 Köln) System und Verfahren zur Zelltyp-spezifischen Translation von RNA-Molekülen in Eukaryoten
PL3596041T3 (pl) 2017-03-15 2023-03-06 Modernatx, Inc. Związek i kompozycje do dokomórkowego dostarczania środków terapeutycznych
US11969506B2 (en) 2017-03-15 2024-04-30 Modernatx, Inc. Lipid nanoparticle formulation
US20210198200A1 (en) 2017-06-14 2021-07-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
WO2019036638A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR PREPARING MODIFIED RNA
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
CN109553686A (zh) * 2017-09-26 2019-04-02 南京安吉生物科技有限公司 一种新型可调控的双嵌合抗原受体t细胞及其构建方法和应用
WO2019140116A2 (en) 2018-01-10 2019-07-18 Rubius Therapeutics, Inc. Amplifiable rnas for therapeutic cell systems
US11875876B2 (en) 2018-06-15 2024-01-16 Massachusetts Institute Of Technology Synthetic 5' UTR sequences, and high-throughput engineering and screening thereof
JP7410135B2 (ja) 2018-09-19 2024-01-09 モデルナティエックス インコーポレイテッド 治療薬の細胞内送達のための化合物及び組成物
CA3113651A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
BR112021014845A2 (pt) 2019-01-31 2021-11-03 Modernatx Inc Métodos de preparação de nanopartículas lipídicas
CN113710353A (zh) 2019-01-31 2021-11-26 摩登纳特斯有限公司 涡流混合器及其相关方法、系统和装置
EP4054652A4 (en) * 2019-11-07 2023-11-22 Icahn School of Medicine at Mount Sinai SYNTHETIC MODIFIED RNA AND USES THEREOF
CN110819707B (zh) * 2019-11-24 2023-07-18 中南大学湘雅医院 一种针对多种来源细胞样本中内部核糖体结合位点元件的高通量鉴定方法
CN114206827B (zh) 2020-04-09 2023-05-23 苏州艾博生物科技有限公司 脂质纳米颗粒组合物
TW202204622A (zh) 2020-04-09 2022-02-01 大陸商蘇州艾博生物科技有限公司 針對冠狀病毒之核酸疫苗
EP4164753A1 (en) 2020-06-30 2023-04-19 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
WO2022020811A1 (en) 2020-07-24 2022-01-27 Strand Therapeutics, Inc. Lipidnanoparticle comprising modified nucleotides
JP2023537887A (ja) 2020-08-20 2023-09-06 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド 脂質化合物及び脂質ナノ粒子組成物
KR20230129479A (ko) 2021-01-08 2023-09-08 스트랜드 세러퓨틱스 인코포레이티드 발현 구성체 및 이의 용도
WO2022152141A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Polymer conjugated lipid compounds and lipid nanoparticle compositions
WO2022152109A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
KR20240013087A (ko) 2021-05-24 2024-01-30 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 지질 화합물 및 지질 나노입자 조성물
EP4204391A1 (en) 2021-10-08 2023-07-05 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
CN116064598B (zh) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
AR127312A1 (es) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2024026490A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Polynucleotides encoding linked antigens and uses thereof
WO2024037578A1 (en) 2022-08-18 2024-02-22 Suzhou Abogen Biosciences Co., Ltd. Composition of lipid nanoparticles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
CA2162056A1 (en) * 1993-01-20 1994-11-10 Christian A. Le Guern Retroviral vectors capable of expressing multimeric proteins from multiple translational initiation sites
US5686120A (en) * 1995-05-22 1997-11-11 Wisconsin Alumni Research Foundation Pre-mRNA processing enhancer and method for intron-independent gene expression
CA2205888A1 (en) 1997-07-11 1999-01-11 John J. Priatel Complementation trap
WO1999025817A2 (en) 1997-11-13 1999-05-27 Regents Of The University Of Minnesota Tc1-based transposon vectors
AU2001231171B2 (en) * 2000-01-28 2007-01-04 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying same

Also Published As

Publication number Publication date
AU2001231171B8 (en) 2001-08-07
EP1274838A1 (en) 2003-01-15
US20090093049A1 (en) 2009-04-09
AU2007202122A1 (en) 2007-05-31
US7456273B2 (en) 2008-11-25
CA2398790A1 (en) 2001-08-02
US7183395B2 (en) 2007-02-27
WO2001055369A9 (en) 2002-10-31
AU3117101A (en) 2001-08-07
AU2001231171B2 (en) 2007-01-04
WO2001055371A1 (en) 2001-08-02
US20040005564A1 (en) 2004-01-08
EP1259602A1 (en) 2002-11-27
WO2001055369A1 (en) 2001-08-02
BR0107943A (pt) 2003-01-28
CA2398541A1 (en) 2001-08-02
AU3120601A (en) 2001-08-07
US20070270580A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
BR0107930A (pt) Métodos de identificação de elementos reguladores transcricionais e translacionais sintéticos, e composições relativas aos mesmos
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
DK0698105T3 (da) Nukleotidsekvenser til styring af ekspressionen af DNAsekvenser i en værtscelle
NO20005613L (no) Nukleinsyremolekyler som koder for enzymer avledet fra hvete og som er involvert i syntesen av stivelse
AU2002359522A8 (en) Compositions and methods of selective nucleic acid isolation
BR9705447A (pt) Microcápsulas usando poliisocianatos de iminooxadiazinadiona
BR9712831A (pt) Inibidores tricìclicos de farnesil proteìna transferase
DE69619132T2 (de) Chimäre oligomere mit einer rns-spaltungsaktivität
SG146577A1 (en) Primer, primer set, and nucleic acid amplification method and mutation detection method using the same
BR9913878A (pt) Sintases
UY26205A1 (es) Derivados de indoloxoacetil piperazina antiviricos
DK0980263T3 (da) Kombinationsprodukt, som kombinerer en nukleinsyre med en substans, der opløser den ekstracellulære matrix, til genterapi
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
ATE275956T1 (de) Veränderung der dns methyltransferase durch kombinationstherapie
BR0007990A (pt) Composição de xampu aquosa
BRPI0403169A (pt) Prognósticos de câncer colorretal
PT942999E (pt) Construcao armadilha de genes para a identificacao e isolamento de genes
NO955119D0 (no) Salmonella identifisering ved polymerasekjedereaksjon
DE60332600D1 (de) Selektive elution von immobilisierten multiplexierten primerverlängerungsprodukten
FR2710074B1 (fr) Gène GRB3-3, ses variants et leurs utilisations.
DE69943129D1 (de) Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs
BRPI0415431A (pt) processos e composições para alteração de fenótipos de sementes
SE9604582D0 (sv) Novel compounds
DE59700511D1 (de) Wässerige Polyurethandispersionen enthaltend Stuktureinheiten abgeleitet von Alkenyl- oder Alkylbernsteinsäure
ATE236250T1 (de) Antisense-sequenzen für die hemmung der expression des adhäsionsmoleküls icam-1

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal: dismissal of application maintained